On April 16, the launch ceremony for Guangzhou's ‘Enterprise Benefit and Win-Win Plan’ was successfully held. The event was guided by the People's Bank of China Guangdong Branch and the Guangdong Financial Bureau Regulatory Bureau, and jointly organized by the Guangzhou Municipal Party Committee Financial Office, Municipal Development and Reform Commission, Municipal Science and Technology Bureau, Municipal Industry and Information Technology Bureau, Municipal Market Supervision Administration, and other units. At the ceremony, DiQi Pharmaceuticals Co., Ltd, as one of the first batch of signing enterprises, formally signed a strategic cooperation agreement with Bank of Guangzhou.

On May 22, the partnership reached a significant milestone—DiQi Pharmaceuticals Co., Ltd. and Bank of Guangzhou signed their first dedicated loan agreement. This signing represents the first substantive outcome since the parties established their strategic partnership in April, and serves as a highly demonstrative practice under Guangzhou's “Enterprise-Benefiting Win-Win Initiative.” Through financial empowerment and industrial synergy, DiQi Pharmaceuticals Co., Ltd will accelerate the advancement of its core pipeline R&D and industrialization strategy, injecting new momentum into the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area.

As a state-owned financial enterprise under Guangzhou municipal administration, Bank of Guangzhou leveraged its strengths to tailor a comprehensive “R&D + Industrial” financial service solution for DiQi Pharmaceuticals Co., Ltd. This solution precisely addresses critical stages in biopharmaceutical enterprise development, including innovative drug R&D and production base construction. It aims to help DiQi Pharmaceuticals Co., Ltd. establish a complete closed-loop ecosystem spanning “R&D - Transformation - Mass Production,” channeling financial “living water” to nurture the blossoming of industrial development.

Liu Feng, Chairman of DiQi Pharmaceuticals Co., Ltd, spoke highly of this collaboration. He stated: "The deep partnership with Guangzhou Bank has come as a timely rain, effectively addressing the funding bottleneck caused by the ‘long cycles and high investment’ inherent in innovative drug R&D. More importantly, through customized financial services, it has enabled precise and efficient resource allocation. This dedicated loan will serve as a powerful catalyst for our corporate development, accelerating breakthroughs in core pipeline technologies. It will expedite the transition of innovative achievements from the laboratory to industrialization and market entry, delivering more and better products to patients while bringing new hope for their health and lives."

The collaboration between DiQi Pharmaceuticals Co., Ltd and Guangzhou Bank marks not only the beginning of complementary strengths and mutual advancement for both parties, but also serves as a vivid example of synergistic innovation between financial institutions and biopharmaceutical enterprises to drive industrial upgrading and development. Moving forward, their partnership will undoubtedly write more remarkable chapters in the innovative development of the biopharmaceutical industry.